慢性肢体威胁性缺血血运重建结局差异:静息痛与组织缺损应分别报告
基于美国全国住院患者样本2009-2013年数据,比较因静息痛(RP)与组织缺损(TL)行下肢血运重建(LER)的结局。TL组腔内治疗比例更高、合并症更多、费用更高,且大截肢率和住院死亡率均显著高于RP组。多变量分析显示TL独立增加大截肢和死亡风险,提示CLTI的TL与RP应分别报告结局。
要点
- 组织缺损患者血运重建后大截肢率和住院死亡率均显著高于静息痛患者。
- 组织缺损是血运重建后大截肢和住院死亡的独立危险因素。
- CLTI的静息痛与组织缺损应分别报告结局以改善基准评估。
核心结论
- 组织缺损与静息痛患者下肢血运重建结局存在显著差异,组织缺损独立关联大截肢和住院死亡。
- 建议将组织缺损与静息痛的血运重建结局分别报告以进行更好的基准评估。
研究设计与样本
- 回顾性分析美国全国住院患者样本(National Inpatient Sample)2009至2013年数据。
- 共纳入218,628例因慢性肢体威胁性缺血行下肢血运重建的患者,其中静息痛76,108例,组织缺损142,519例。
- 比较两组患者特征、Charlson合并症指数、住院时长、住院大截肢率和死亡率,并采用多变量回归分析预测住院死亡和大截肢。
主要发现
- 组织缺损组行腔内血运重建比例高于静息痛组(48.7% vs. 31.3%,P < 0.001)。
- 组织缺损组Charlson合并症指数≥3的比例更高(40.3% vs. 22.9%,P < 0.001)。
- 组织缺损组平均费用更高($31,470 vs. $23,795,P < 0.001)。
- 组织缺损组大截肢率(6.6% vs. 1.3%,P < 0.001)和住院死亡率(1.9% vs. 0.9%,P < 0.001)均显著高于静息痛组。
- 多变量分析显示组织缺损独立关联大截肢(OR 4.93,95%CI 4.18-5.81)和死亡(OR 1.42,95%CI 1.16-1.74)。
临床怎么用
- 临床评估CLTI患者时应区分静息痛与组织缺损,组织缺损患者血运重建前需更充分的风险评估和围术期管理。
- 质量评估和基准比较时,应将组织缺损与静息痛的血运重建结局分开报告。
局限性
- 研究基于住院患者样本,仅反映住院期间结局,缺乏长期随访数据。
- 回顾性设计可能存在编码偏倚和未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic limb-threatening ischemia (CLTI) manifests as rest pain (RP) and tissue loss (TL). Outcomes of lower extremity revascularization (LER) for CLTI have traditionally been evaluated as a single entity and compared with claudication. We hypothesize that patients presenting with TL have worse short-term outcomes after LER, compared to patients with RP. METHODS: The National Inpatient Sample was reviewed between 2009 and 2013. All patients undergoing LER for TL and RP were identified. Patient characteristics, Charlson Comorbidity Index (CCI), length of stay, rates of inpatient major amputation, and mortality after LER were noted. Multivariable regression analysis was performed to identify predictors of inpatient mortality and major amputation between the 2 groups. RESULTS: A total of 218,628 patients underwent LER (RP = 76,108, TL = 142,519). Patients with TL were more likely to undergo endovascular LER (RP = 31.3% vs. TL = 48.7%; P < 0.001). Patients with TL had higher comorbidities as suggested by increased likelihood of having CCI ≥3 (RP = 22.9% vs. TL = 40.3%; P < 0.001). The mean costs were significantly higher in the TL group (RP = $23,795 vs. TL = $31,470; P < 0.001). There was a significantly higher rate of major amputation (RP = 1.3% vs. TL = 6.6%; P < 0.001) and inpatient mortality (RP = 0.9% vs. TL = 1.9%; P < 0.001) after LER for TL. On multivariable analysis, TL was independently associated with increased major amputation (odds ratio [OR] 4.93, 95% confidence interval [CI] 4.18-5.81) and increased mortality (OR 1.42, 95% CI 1.16-1.74) compared to RP. CONCLUSIONS: There is significant discrepancy in outcomes of LER for TL and RP. TL is independently associated with major amputation and inpatient mortality. Outcomes of LER for TL and RP should be reported separately for better benchmarking.
引用
- Brahmandam A, Gholitabar N, Cardella J, et al. Discrepancy in Outcomes after Revascularization for Chronic Limb-Threatening Ischemia Warrants Separate Reporting of Rest Pain and Tissue Loss. Ann Vasc Surg. 2020. PMID: 32659417. doi:10.1016/j.avsg.2020.06.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。